Skip to main content

Table 1 Eligibility criteria of this study

From: Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma

Eligibility Criteria Clinical stage I, II or III (M0; N0-2; T1-3) pleural mesothelioma
Performance status 0 to 1on the ECOGa performance status schedule
No previous surgical resection of mesothelioma
No previous radiation therapy
Estimated life expectancy of at least 12 weeks
Adequate cardiac function
Must be judged suitable to the therapy by medical oncologist and thoracic surgeon.
Pulmonary function tests: FEV1b >0.8, DLCOc >35% of predicted postoperative FEV1 (ppoFEV1)
ABGd Predicted postoperative pCO2 <50.
Adequate bone marrow reserve:
 · absolute neutrophil (segmented and bands) count (ANC) ≥1.5 × 109/L,
 · Platelets ≥100 × 109/L, and hemoglobin ≥9 g/dL.
Hepatic: bilirubin ≤1.5 times the upper limit of normal (× ULN), alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤3.0 × ULN.
Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug.
  Geographical condition must not hamper the compliance with the study protocol and follow-up schedule.
  1. a Eastern Cooperative Oncology Group;b Forced Expiratory Volume;c Diffusing Capacity of the Lung for Carbon monoxide;d Arterial Blood Gas.